U.S. Equity Indexes Edge Higher on Low Volume, Volatility Ahead of FOMC Meeting

Helping the NASDAQ Composite to outperform the other majors were shares of Facebook and Netflix, which gained 4.2% and 3.2%, respectively. Amazon posted a 0.9% gain, Google parent Alphabet rose 0.7% and Apple rallied 0.6%.
James Hyerczyk
U.S. Stock Indexes

The major U.S. equity markets edged higher on Monday with technology shares leading the way. Volatility and volume were below average, however, as most major players took to the sideways ahead of the start of the U.S. Federal Reserve two-day Federal Open Market Committee (FOMC) meeting on Tuesday and the release of the central bank’s interest rate and monetary policy decisions on Wednesday.

In the cash market, the benchmark S&P 500 Index settled at 2889.67, up 2.69 or +0.10%. The blue chip Dow Jones Industrial Average closed at 26112.53, up 22.92 or +0.09% and the technology-based NASDAQ Composite finished at 7845.02, up 48.36 or +0.63%.

Helping the NASDAQ Composite to outperform the other majors were shares of Facebook and Netflix, which gained 4.2% and 3.2%, respectively. Amazon posted a 0.9% gain, Google parent Alphabet rose 0.7% and Apple rallied 0.6%.

Dow components Apple and Disney were mixed with shares of Disney slipping 0.5% after an analyst at Imperial Capital downgraded the stock to in-line from outperform, citing a “record” valuation.

The S&P 500 Index posted limited gains as oil prices eased, pressuring the S&P Energy Sector.

Pfizer Acquires Array BioPharma

In other news, Array BioPharma shares jumped nearly 60% after the company was acquired by Pfizer for $10.6 billion. Monday’s deal for Array, which garnered a 62% premium to its closing price Friday, suggests just how important the market for cancer drugs is for the world’s biggest pharmaceutical companies, according to the Wall Street Journal.

WSJ went on to say that Array’s two drugs, Braftovi and Mektovi, are currently approved to treat skin-cancer patients with certain genetic alterations. The drugs could also play a role in treating some colon and rectal cancer patients, if studies pan out.

Pfizer’s cancer drugs are projected to generate $8.3 billion in sales this year, according to EvaluatePharma.

Sotheby’s Goes Private

Sotheby’s auction house announced Monday an agreement to be acquired by BidFair USA, a venture wholly owned by French media entrepreneur and art collector Patrick Drahi.

According to CNBC, the transaction, if approved by shareholders, would result in Sotheby’s returning to private ownership after 31 years as a public company traded on the New York Stock Exchange.

The stock rallied more than 57% on Monday morning following the news.

Don't miss a thing!

Discover what's moving the markets. Sign up for a daily update delivered to your inbox

Latest Articles

See All

Expand Your Knowledge

See All

Top Promotions

Top Brokers

IMPORTANT DISCLAIMERS
The content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party's services, and does not assume responsibility for your use of any such third party's website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.
RISK DISCLAIMER
This website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.
FOLLOW US